

Relationship between CYP2C19 polymorphisms and weight gain in epilepsy patients treated with divalproex sodium: does gender matter?



Wardah Rahmatul Islamiyah^{1,2}, Nasronudin^{3,4*}, Abdulloh Machin²,
lin Ernawati⁵, Paulus Sugianto²

¹Doctoral Program of Medical Science,
Faculty of Medicine, Universitas

Airlangga, Surabaya 60132, Indonesia;

²Department of Neurology, Faculty of
Medicine, Universitas Airlangga - Dr.
Soetomo General Hospital, Surabaya,
Surabaya, 60132, Indonesia;

³Department of Internal Medicine,
Faculty of Medicine, Universitas
Airlangga, Surabaya, Surabaya, 60132,
Indonesia;

⁴Department of Internal Medicine,
Universitas Airlangga Hospital, Surabaya,
60132, Indonesia;

⁵Pharmacy Academy Surabaya, Surabaya,
East Java, 60231, Indonesia;

*Corresponding author:

Nasronudin;

Department of Internal Medicine, Faculty
of Medicine, Universitas Airlangga-
Universitas Airlangga Hospital, 60132,
Indonesia;

nasronudin@fk.unair.ac.id

Received: 2022-09-24

Accepted: 2022-10-22

Published: 2022-11-29

ABSTRACT

Introduction: Epilepsy is an unprovoked seizure caused by an abnormal paroxysmal neuronal release in the brain. One of epilepsy treatments is anti-epileptic drug divalproex sodium. It is often prescribed to control seizures but it increases body weight. Weight gain may decrease the effectiveness of epilepsy treatment and cause endocrine disorders. CYP2C19 polymorphism may help physicians map patients vulnerable to weight gain due to divalproex sodium. This study aimed to determine the relationship between CYP2C19 polymorphisms and the incidence of weight gain based on gender in epilepsy patients treated with divalproex sodium.

Methods: This cross-sectional study consisted of 17 male and 23 female patients. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to identify CYP2C19 polymorphism which was grouped into: extensive metabolizer, intermediate metabolizer and poor metabolizer. The results were analyzed using Chi-squared test to determine the relationship between CYP2C19 and each variable (gender, age, epilepsy types, valproic acid types, family history of obesity and presence of weight gain) based on of gender.

Results: The results showed that there was no statistically significant association between CYP2C19 polymorphisms and gender-based epilepsy patients groups ($p > 0.05$). We found that most of the subjects in this study were women with an increase in body weight by 57.5%. There was no association of CYP2C19 polymorphism with type of divalproex sodium, dose of divalproex sodium, length of treatment, type of epilepsy and family history of obesity.

Conclusion: There is no significant association between CYP2C19 polymorphism and weight gain between genders in epilepsy patients.

Keywords: CYP2C19 polymorphism, epilepsy, divalproex sodium, body weight, gender.

Cite This Article: Islamiyah, W.R., Nasronudin., Machin, A., Ernawati, I., Sugianto, P. 2022. Relationship between CYP2C19 polymorphisms and weight gain in epilepsy patients treated with divalproex sodium: does gender matter?. *Bali Medical Journal* 11(3): 1800-1804. DOI: 10.15562/bmj.v11i3.3748

INTRODUCTION

Epilepsy is a cerebral disease due to abnormal paroxysmal neuronal release in the brain and one of the epilepsy therapies is using antiepileptic/anti-seizure drugs.¹⁻⁴ The most commonly prescribed anti-seizure is valproic acid (VPA). Since VPA has been known to cause a serious side effects, it is also available as the combination with sodium valproate to be divalproex sodium.^{5,6} Both produce similar treatment results and can be used interchangeably under equivalent dose adjustment.⁷ VPA or divalproex sodium has broad indications, besides seizures and epilepsy, such as bipolar psychiatric disorders, schizophrenia, borderline personality disorder, and

migraine prophylaxis.^{7,8} Despite having a broad spectrum, one of the most widely reported side effects of divalproex sodium is weight gain.⁹ Weight gain is also at risk of decreasing patient adherence and discontinuing antiepileptic drugs. Drug-induced weight gain is also responsible for the incidence of endocrine disorders (menstrual disorders, polycystic ovaries, and hyperandrogenism).^{8,10,11}

The frequency of weight gain occurrence after consuming divalproex sodium or VPA still varies. Two studies from Italy and Austria reported a significant increase in body weight (≥ 5 kg) occurred in 23.5% of men and 43.6% of women who were treated with VPA.^{12,13} Other studies also showed an increase in body weight for 2 kg after 1 month of

therapy.^{12,14} Weight gain also occurred in 71% of VPA users and 58% in children and adolescents receiving VPA. This weight gain is more common in women than men.^{8,15,16} A study in Japan showed that VPA increased serum testosterone levels in epilepsy patients, especially those who were treated with VPA since less than 20-year-old.⁹ Testosterone positively correlates with orexigenic ghrelin level, conveying hunger signals to the brain.^{17,18}

In clinical practice, not all patients experience weight gain despite taking VPA or divalproex sodium at high doses for a long period of time. This raises the suspicion of the influence of genetic variation on the incidence of weight gain due to VPA. Many studies have identified genes associated with VPA-induced

weight gain and have focused on factors influencing the molecular pathways involved in appetite stimulation and inhibition of food satisfaction.¹⁰ CYP2C19 is one of the predominant enzymes in divalproex sodium metabolism. Three CYP2C19 genotypes were grouped in this study, namely the homozygous wild type/extensive metabolizer (EM) allele of CYP2C19*1/*1, the heterozygous intermediate metabolizer (IM) allele of CYP2C19*1/*2 or CYP2C19*1/*3 and the heterozygous poor metabolizer (PM) allele of CYP2C19*2/*3.

In the group of patients with an increased body weight, 70% had an EM genotype while the PM population was only 5%. However, in the normal or decreased weight group, the EM and PM populations were balanced (50%). In general, the frequency of PM in Asian population is 15-25%.⁹ This finding was preceded by a study, by the same researchers, that demonstrated an association between CYP2C19 polymorphisms and weight gain in patients receiving VPA. It was concluded that in women receiving VPA, body mass index ($p=0.002$) and weight gain ($p=0.032$) were higher in patients with heterozygous EM and PM CYP2C19 polymorphisms than in homozygous EM. But, in the follow-up study, the higher BMI and weight gain were found in heterozygous EM.⁹ Different results were also shown by a recent study that the risk of weight gain was three times higher in CYP2C19*1/*2 and CYP2C19*2/*2 than in CYP2C19*1/*1 of 108 VPA-treated epilepsy patients.¹⁹

The high incidence of weight gain after divalproex sodium or VPA treatment in female patients compared to male patients raises the suspicion of a different role of sex hormones in CYP2C19 gene polymorphisms and body weight by sex. Another study found an association of CYP2C19 polymorphisms with divalproex sodium, increased appetite and testosterone metabolism.²⁰ The differences in population, genotype, study methods and other factors might affect the study results obtained. This study was conducted to determine the relationship between CYP2C19 gene polymorphisms and weight gain associated with sex, based on divalproex sodium types, daily dosage,

length of treatment, epilepsy types, family history of obesity, testosterone level and estrogen level.

METHODS

Study design and sample collection

This analytical cross-sectional study consisted of two sample groups and was compared simultaneously. The patients had been treated with divalproex sodium and divalproex sodium extended-release (ER) monotherapy at Airlangga University Hospital for 6 months. The subjects of this study were epilepsy patients who received valproic acid. They were selected using purposive consecutive sampling method based on inclusion and exclusion criteria. The inclusion criteria were 18-50 years old, with no history of impaired liver or kidney function, willing to participate and follow all study procedures. Specifically for the female patients, they had had regular menstrual cycles. The exclusion criteria were pregnant patients, who had a history of weight gain >2.5 kg in six months before being treated with divalproex sodium and divalproex sodium ER, used hormonal contraception, corticosteroid, or herbal medicine, and followed a weight gain or loss program. From the calculation of the sample size for two populations, the total sample size was 40 patients.

PCR-RFLP test

The materials for DNA isolation consisted of lysis buffer for cell membranes (CMLB), lysis buffer for nuclear membranes (NMLB), Tris-EDTA (TE) buffer (10 mM Tris HCl pH 7.4 and 0.1 mM Na₂EDTA) and Tris-borate-EDTA (TBE) buffer 5x (54 g Trisbase, 27.5 g boric acid, 20 mL 0.5 M Na₂EDTA pH 8). Primers used for polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) test was shown in [Table 1](#).

Genotyping

The DNA was isolated from 3 ml EDTA-anticoagulated blood using an automatic gene extractor. CYP2C19 was genotyped using real-time PCR. Four reaction solutions were added to each sample according to the instruction. The internal reference probe was added to control the quality of the reaction. Each experiment was performed using a positive and a

blank control. The PCR reaction consisted of a 30-minute hold at 37°C, a 15-minute hold at 95°C, followed by 30 cycles of 30 s at 95°C, 30 s at 56°C and 45 s at 65°C. The samples were amplified with GeneAmp PCR system 2400. When the amplification curve was obtained, the samples were analyzed using the cycle threshold value (CT-value). MyTaq HS Red Mix reagent, PCR Grade Water and primer were prepared at room temperature to amplify the genomic DNA. The remainder of the extracted DNA was stored at 2-8°C for 24 hours or -70°C for a longer period of storage. The CYP2C19 genotypes were identified with gel electrophoresis device and gel documentation XR. The results were categorized into three groups: patients with at least two *2 or *3 alleles (*2/*2, *2/*3, or *3/*3) as poor metabolizers (PM), those with one *2 or *3 allele (*1/*2 or *1/*3) as intermediate metabolizers (IM) and those without a *2 or *3 alleles (*1/*1) were classified as extensive metabolizers (EM).

Estrogen level examination

Blood sample was taken before 10 a.m. and processed to be separated from serum. It was stored at room temperature (20-25 °C). The blood containing precipitation was centrifuged at 10,000g for less than 2 hours to avoid evaporation. Before inserting the estradiol kit reagent into the apparatus of Electrochemiluminescence Immunoassay (ECLIA), the sample was inverted 30 times and gently shaken to suspend the blood sample. The complete suspension was confirmed visually, followed by the kit reagent removal. The sample was then stored at 2-9°C.

Free testosterone examination

The level of testosterone was analysed using enzyme immunoassay analysis (EIA). Blood sample was taken before 10 a.m. A total of 4-5 mL of each serum-free blood sample was stored in a centrifuge tube at 4°C for 24 hours or less than -10°C if it is analysed for more than 24 hours. Each calibrator, control, and specimen was pipetted 25 µL into the labelled wells. A total of 100 µL of conjugate working solution were added into each well and shaken for 10 seconds. The plate was incubated at 37°C for one hour. The wells

were washed three times with 350 μ L of diluted wash buffer in each well and dried carefully with absorbent paper. As much as 150 μ L of 3,3',5,5'-tetramethylbenzidine (TMB) substrate were pipetted into each well. The plate was incubated at 37°C for 10-15 minutes and pipetted 50 μ L stopping solution into each well. The results were read in a microwell plate reader at 450 nm within 20 minutes.

Statistical analysis

The association between the CYP2C19 genotypes and patients based on divalproex sodium type, dosage, duration of therapy, epilepsy types, family history

of obesity, free testosterone, estrogen level were analysed using Chi-squared test. The results were considered significant at $p < 0.05$. All analyses were conducted using SPSS software (NY, USA).

RESULTS

There were 40 epilepsy patients included in this study. They were divided into two groups, patients with increased bodyweight and no increase in bodyweight group (Table 2).

The distribution of all three polymorphism groups were 60% (n=24) as EM, 37.5% (n=15) as IM and 2.5% (n=1)

as PM. In male patients, the EM group was 11 (27.5%) and the IM group was 6 (15%). The EM group was 13 (32.5%) and the IM group was 9 (22.5%) in female patients. The IM and PM groups were mostly found in female group (Table 3).

The relationship analysis between CYP2C19 polymorphisms and sample variables (divalproex sodium types, dosage, length of treatment, epilepsy types, family history of obesity, free testosterone and estrogen level) is presented in Table 4. We found no significant relationship in CYP2C19 polymorphisms towards both of patients groups, in terms of divalproex sodium type (male vs. female, $p=0.162$ vs $p=0.414$), length of treatment (male vs. female, $p=1.000$ vs $p=0.478$) and family history of obesity (male vs. female, $p=0.640$ vs $p=1.000$).

Table 1. Primers used in PCR-RFLP test.

| Genes | Primer | Sequence |
|-----------|---------|---------------------------|
| CYP2C19*2 | Forward | 5'-CAGAGCTTGGCATATTGTATC |
| | Reverse | 5'-GTAAACACAAAAGTAGTCAATG |
| CYP2C10*3 | Forward | 5'AAATTGTTTCCAATCATTAGCT |
| | Reverse | 5'-ACTTCAGGGCTTGGTCAATA |

Table 2. Demographic characteristics of the included patients.

| Demographic characteristics | Total (n) | Percentage (%) |
|---|-----------|----------------|
| Gender | | |
| Male | 17 | 42.5 |
| Female | 23 | 57.5 |
| Age (years) | | |
| 18-20 (inclusion criteria >18) | 9 | 22.5 |
| 21-30 | 6 | 15.0 |
| 31-40 | 6 | 15.0 |
| 41-50 | 18 | 45.0 |
| 51-60 | 1 | 2.5 |
| Epilepsy type | | |
| General | 19 | 47.5 |
| Focal | 20 | 50.0 |
| Absence | 1 | 2.5 |
| Divalproex sodium type | | |
| Divalproex sodium | 20 | 50.0 |
| Divalproex sodium ER (extended release) | 20 | 50.0 |
| Family history of obesity | | |
| Yes | 28 | 70.0 |
| No | 12 | 30.0 |
| Weight gain | | |
| Yes | 20 | 50.0 |
| No | 20 | 50.0 |

Table 3. Distribution of CYP2C19 polymorphisms based on gender of the patients.

| Gender | CYP2C19 polymorphism | | |
|--------|----------------------|----------------------|------------|
| | *1/*1 (EM) | *1/*2 and *1/*3 (IM) | *2/*3 (PM) |
| Male | 11 (27.5%) | 6 (15%) | 0 (0%) |
| Female | 13 (32.5%) | 9 (22.5%) | 1 (2.5%) |
| Total | 24 (60%) | 15 (37.5%) | 1 (2.5%) |

DISCUSSION

There were 40 patients included in this study. Based on Table 2, the patients were mostly female (57.5%) with the age ranging between 41 and 50 years (45%). They were almost equally distributed to generalized epilepsy (47.5%) and focal epilepsy (50%). During divalproex sodium therapy, women with generalized epilepsy are vulnerable to anovulatory cycles, polycystic ovaries and obesity.²¹ A significant rise of testosterone level is especially noticeable in women who begin treatment at less than 20 years, suggesting that young female epilepsy patients are at higher risk to the effects of divalproex sodium.²²

Based on observations and interviews, 70% of the patients had a family history of obesity. It may cause other family members to be more likely to be obese and gain weight due to divalproex sodium consumption.^{23,24} This study suggested no significant relationship between family history of obesity and the CYP2C19 in causing increased body weight of divalproex sodium-treated patients.

Reproductive hormones, like testosterone and estrogen, are important modulators of energy balance and food intake.²⁵ CYP2C19 has been linked to the metabolism of estrogen and testosterone. CYP2C19 is able to catalyze the oxidative catalysis of testosterone to produce 2b-, 6b-, 15b-, and 16b-hydroxytestosterone.²⁶

Table 4. Relationship of CYP2C19 polymorphism and clinical parameters in epilepsy patients based on gender.

| Parameter | Male | | | p-value | Female | | | p-value |
|-----------------------------|-----------|----------|--------|---------|----------|----------|----------|---------|
| | EM (%) | IM (%) | PM (%) | | EM (%) | IM (%) | PM (%) | |
| Divalproex sodium type | | | | 0.162 | | | | 0.414 |
| Divalproex sodium ER | 8 (80.0) | 2 (20) | 0 (0) | | 4 (40) | 6 (60) | 0 (0) | |
| Divalproex sodium | 3 (42.9) | 4 (57) | 0 (0) | | 8 (60) | 4 (33) | 1 (7) | |
| Dosage (mg per day) | | | | 0.102 | | | | 0.590 |
| 750–1500 | 5 (100) | 0 (0) | 0 (0) | | 1 (33.3) | 1 (33.3) | 1 (33.3) | |
| <750 | (50) | 6 (50) | 0 (0) | | 11 (55) | 9 (45) | 0 (0) | |
| Length of treatment (month) | 11 (64.7) | 6 (35.3) | 0 (0) | 1.000 | 12 (52) | 10 (43) | 1 (3) | 0.478 |
| Epilepsy types | | | | | | | | 0.414 |
| General | 6 (75) | 2 (25) | 0 (0) | 0.620 | 7 (64) | 3 (27) | 1 (9) | |
| Focal/Absence | 5 (55.6) | 4 (44.4) | 0 (0) | 0.620 | 5 (42) | 7 (58) | 0 (0) | |
| Family history of obesity | | | | 0.640 | | | | 1.000 |
| No | 4 (57) | 3 (42.9) | 0 (0) | | 3 (60) | 1 (20) | 1 (20) | |
| Yes | 7 (70) | 3 (30) | 0 (0) | | 9 (50) | 9 (50) | 0 (0) | |
| Free testosterone | | | | 0.644 | | | | 1.000 |
| Normal | 7 (70) | 3 (30) | 0 (0) | | 11 (52) | 9 (43) | 1 (5) | |
| Increase | 1 (100) | 0 (0) | 0 (0) | | 1 (100) | 0 (0) | 0 (0) | |
| Decrease | 4 (66.1) | 2 (33.9) | 0 (0) | | 0 (0) | 1 (100) | 0 (0) | |
| Estrogen level | | | | 0.515 | | | | 0.090 |
| Normal | 8 (57.1) | 6 (42.9) | 0 (0) | | 12 (6) | 7 (35) | 1 (5) | |
| Increase | 2 (66.7) | 1 (33.3) | 0 (0) | | 0 (0) | 2 (100) | 0 (0) | |
| Decrease | 0 (0) | 0 (0) | 0 (0) | | 0 (0) | 1 (100) | 0 (0) | |

A high level of testosterone in women may cause insulin resistance and abdominal fat accumulation.²⁶ In men, the situation appears to be exactly the contrary, with more abdominal fat is associated with lower testosterone levels.²⁶ Estrogen may stimulate appetite and consequently cause weight gain. According to another study, CYP2C19 heterozygous EM and PM is associated with the increased level of testosterone and estrogen that induce weight gain, primarily on female epilepsy patients treated with divalproex sodium, though the actual mechanism remains unclear.⁹ In this study, the three CYP2C19 genotypes were mostly distributed in female patients, where EM group was 13 (32.5%), IM group was 9 (22.5%) and PM group was 1 patient (2.5%) (Table 3). However, we found no significant relationship between the reproductive hormones (testosterone and estrogen) and CYP2C19 polymorphisms in inducing weight gain of divalproex sodium-treated patients, whether male or female.

Divalproex sodium inhibits the CYP2C19 to bind with a substrate which is needed to catalyze the conversion of androgens to estrogens. The inhibition

of divalproex sodium works by binding to the enzyme's active site. Consequently, when the enzyme binds to a substrate (e.g., testosterone), the enzyme becomes inactive and the androgen conversion is disrupted.²⁷ In those with IM and PM polymorphisms, the divalproex sodium will cause a lower testosterone catalysis and increase the testosterone level. The excessive testosterone level may cause a rise of appetite and body weight.^{26,28}

The average dose of divalproex sodium (mg/day) and the gender of the patients was not significantly associated. There is also no relationship between dose of divalproex sodium (mg/day) and CYP2C19 polymorphisms (Table 4). This result is different from a study in Japan that found a significant association between CYP2C19 cytochrome polymorphisms and weight gain, also a higher incidence of overweight was higher in women who lost one or two CYP2C19 alleles ($p < 0.05$).⁹

Based on this study, there was no significant relationship between the CYP2C19 polymorphisms and gender-based bodyweight in epilepsy patients treated with divalproex sodium. This is similar to a previous finding that there

was no significant relationship between gender of the patients and valproic acid in inducing weight gain ($p > 0.05$).⁹

CONCLUSION

Our data suggest no association between CYP2C19 polymorphism and weight gain, in divalproex sodium-treated epilepsy patients. The result is not differed whether on male or female patients.

ETHICAL APPROVAL

The study protocol was approved by the ethical committee of Faculty of Medicine, Universitas Airlangga, Indonesia (No. 128/EC/KEPK/FKUA/2021).

COMPETING INTERESTS

The authors declare no conflict of interest.

GRANT INFORMATION

This study received no external funding.

ACKNOWLEDGMENTS

We would like to thank the staffs at Department of Neurology, Dr. Soetomo

General Academic Hospital, Surabaya, Indonesia.

AUTHOR CONTRIBUTION

All author had contributed in manuscript writing and agreed for the final version of the manuscript for publication.

REFERENCES

- Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. *Lancet* [Internet]. 2015;385(9971):884–98. Available from: [http://dx.doi.org/10.1016/s0140-6736\(14\)60456-6](http://dx.doi.org/10.1016/s0140-6736(14)60456-6)
- Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy—a review. *Epilepsy Res* [Internet]. 2009/04/15. 2009 Jul;85(1):31–45. Available from: <https://pubmed.ncbi.nlm.nih.gov/19369037>
- Sekarsari D, Kalanjati VP, Machin A, Gunawan PI. Profile Of Epilepsy Patients In Pediatric Ward At Dr. Soetomo General Academic Hospital, Surabaya, Indonesia In The Period Of January-December 2017. *Maj Biomorfologi* [Internet]. 2020;30(2):34. Available from: <http://dx.doi.org/10.20473/mbiom.v30i2.2020.34-38>
- Kurniawaty Y, Kalanjati VP. Mechanism of neurological disorders in epilepsy. *Biomorfologi Magazine*. 2013;26(1):16–21.
- Ardianto C, Wardani HA, Nurrahmi N, Rahmadi M, Khotib J. Alpha-lipoic acid ameliorates sodium valproate-induced liver injury in mice. *Vet world* [Internet]. 2020/05/22. 2020 May;13(5):963–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/32636594>
- Ratri DMN, Rahmadi M, Islamiyah WR, Harum NF. Overview of therapeutic changes in antiepileptic drugs in adult patients. *J Basic Clin Physiol Pharmacol* [Internet]. 2020;30(6). Available from: <http://dx.doi.org/10.1515/jbcpp-2019-0346>
- Schwartz TL, Massa JL, Gupta S, Al-Samarrai S, Devitt P, Masand PS. Divalproex Sodium Versus Valproic Acid in Hospital Treatment of Psychotic Disorders. *Prim Care Companion J Clin Psychiatry* [Internet]. 2000 Apr;2(2):45–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/15014582>
- Li H, Wang X, Zhou Y, Ni G, Su Q, Chen Z, et al. Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. *Int J Neuropsychopharmacol* [Internet]. 2015 Mar 3;18(7):pyv021–pyv021. Available from: <https://pubmed.ncbi.nlm.nih.gov/25740917>
- Noai M, Soraoka H, Kajiwara A, Tanamachi Y, Oniki K, Nakagawa K, et al. Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. *Acta Neurol Scand* [Internet]. 2015;133(3):216–23. Available from: <http://dx.doi.org/10.1111/ane.12473>
- Martin CK, Han H, Anton SD, Greenway FL, Smith SR. Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. *J Psychopharmacol* [Internet]. 2008/06/26. 2009 Sep;23(7):814–25. Available from: <https://pubmed.ncbi.nlm.nih.gov/18583434>
- Mahmud AA, Anu UH, Foysal KA, Hasan M, Sazib SM, Ragib AA, et al. Elevated serum malondialdehyde (MDA), insulin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH), and reduced antioxidant vitamins in polycystic ovarian syndrome patients. *Narra J* [Internet]. 2022;2(1). Available from: <http://dx.doi.org/10.52225/narra.v2i1.56>
- Verrotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. *Epilepsia* [Internet]. 2010;51(2):268–73. Available from: <http://dx.doi.org/10.1111/j.1528-1167.2009.02206.x>
- El-Khatib F, Rauchenzauner M, Lechleitner M, Hoppichler F, Naser A, Waldmann M, et al. Valproate, weight gain and carbohydrate craving: A gender study. *Seizure* [Internet]. 2007;16(3):226–32. Available from: <http://dx.doi.org/10.1016/j.seizure.2006.12.009>
- Luef G, Abraham I, Trinka E, Unterberger I, Hoppichler F, Bauer G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. *Neurology* [Internet]. 2001;57(3):565.2-566. Available from: <http://dx.doi.org/10.1212/wnl.57.3.565-a>
- Grosso S, Mostardini R, Piccini B, Balestri P. Body Mass Index and Serum Lipid Changes During Treatment with Valproic Acid in Children with Epilepsy. *Ann Pharmacother* [Internet]. 2009;43(1):45–50. Available from: <http://dx.doi.org/10.1345/aph.11414>
- Carlson JA, Dabiri G, Cribier B, Sell S. The immunopathobiology of syphilis: the manifestations and course of syphilis are determined by the level of delayed-type hypersensitivity. *Am J Dermatopathol* [Internet]. 2011 Jul;33(5):433–60. Available from: <https://pubmed.ncbi.nlm.nih.gov/21694502>
- Borgquist A, Meza C, Wagner EJ. The role of AMP-activated protein kinase in the androgenic potentiation of cannabinoid-induced changes in energy homeostasis. *Am J Physiol Endocrinol Metab* [Internet]. 2014/12/30. 2015 Mar 15;308(6):E482–95. Available from: <https://pubmed.ncbi.nlm.nih.gov/25550281>
- Patterson M, Bloom SR, Gardiner J V. Ghrelin and appetite control in humans—Potential application in the treatment of obesity. *Peptides* [Internet]. 2011;32(11):2290–4. Available from: <http://dx.doi.org/10.1016/j.peptides.2011.07.021>
- Mani B, Nair PP, Sekhar A, Kamalanathan S, Narayan SK, Kesavan R. CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study. *Epilepsy Res* [Internet]. 2021;177:106786. Available from: <http://dx.doi.org/10.1016/j.epilepsyres.2021.106786>
- Aruwatari J, Ishitsu T, Nakagawa K. Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. *Pharmaceuticals (Basel)* [Internet]. 2010 Aug 20;3(8):2709–32. Available from: <https://pubmed.ncbi.nlm.nih.gov/27713373>
- Morrell MJ, Giudice L, Flynn KL, Seale CG, Paulson AJ, Doñe S, et al. Predictors of ovulatory failure in women with epilepsy. *Ann Neurol* [Internet]. 2002;52(6):704–11. Available from: <http://dx.doi.org/10.1002/ana.10391>
- Isojärvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllylä V V. Obesity and endocrine disorders in women taking valproate for epilepsy. *Ann Neurol* [Internet]. 1996;39(5):579–84. Available from: <http://dx.doi.org/10.1002/ana.410390506>
- van der Sande MA. A template for improved prevention and control of cardiovascular disease in sub-Saharan Africa. *Health Policy Plan* [Internet]. 2001;16(4):345–50. Available from: <http://dx.doi.org/10.1093/heapol/16.4.345>
- McIntyre RS, Konarski JZ, Keck PE. Psychotropic-Induced Weight Gain: Liability, Mechanisms and Treatment Approaches [Internet]. *Obesity and Mental Disorders*. Informa Healthcare; 2006. p. 307–54. Available from: <http://dx.doi.org/10.3109/9780849374517.014>
- Hirschberg AL. Sex hormones, appetite and eating behaviour in women. *Maturitas* [Internet]. 2012;71(3):248–56. Available from: <http://dx.doi.org/10.1016/j.maturitas.2011.12.016>
- Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR. Characterization of testosterone 11 β -hydroxylation catalyzed by human liver microsomal cytochromes P450. *Drug metab dispos* [Internet]. 2005;33(6):714–8. Available from: <http://dx.doi.org/10.1124/dmd.104.003327>
- Muftuoglu Y, Mustata G. Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis. *Reprod Biol Endocrinol* [Internet]. 2011 Jun 21;9:92. Available from: <https://pubmed.ncbi.nlm.nih.gov/21693043>
- Usmani KA, Rose RL, Hodgson E. Inhibition and Activation of the Human Liver Microsomal and Human Cytochrome P450 3A4 Metabolism of Testosterone by Deployment-Related Chemicals. *Drug Metab Dispos* [Internet]. 2003;31(4):384–91. Available from: <http://dx.doi.org/10.1124/dmd.31.4.384>



This work is licensed under a Creative Commons Attribution